Clinical trials: HAART-treated
HIV Infections
ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
This study aims to investigate whether patients switching their backbone from Kivexa to Truvada, who already have raised total cholesterol prior to switching, have an improvement in their total cholesterol after 12 weeks of…
- Trial name
- ROCKET I (NCT00615810)
- Testing
- Atripla, Kivexa plus Sustiva
- Where
- United Kingdom
- Volunteers
- 159 people
- Sponsor
- Gilead Sciences
HIV Infections
Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa
HIV infected people often must take anti-HIV drugs for long periods, leading to long-term drug exposure and toxicity. Interruptions in anti-HIV therapy, also known as structured treatment interruptions (STIs), may have few…
- Trial name
- NCT00100646
- Testing
- Structured treatment interruption, Lamivudine, Lopinavir/Ritonavir
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- The Wistar Institute
HIV Infections
An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)
In southern Africa, TB is the most common first AIDS-defining condition. Initiating Antiretroviral therapy (ART) in HIV positive TB patients will lead to the inclusion of the majority of HIV/AIDS patients currently fulfilling the…
- Trial name
- eASP (NCT00408642)
- Testing
- Enhanced adherence support, Standard adherence support
- Where
- South Africa
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
HIV Infections
The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV
The purpose of this study is to determine the number of newly formed CD4 cells in children who have taken anti-HIV drugs. The study will also evaluate the effectiveness of the new CD4 cells in producing an immune response to…
- Trial name
- NCT00004735
- Testing
- Tetanus toxoid, Hepatitis A Vaccine (Inactivated)
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, Tuberculosis
Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis
Aim of the study is to determine optimal time to initiate anti-retroviral therapy in HIV/TB co-infected patients who recently started treatment for Tuberculosis by comparing immediate versus deferred initiation of HAART.
- Trial name
- TB-HAART (NCT01315301)
- Testing
- Comparison of different treatment strategies
- Where
- Ethiopia
- Volunteers
- 450 people
- Sponsor
- Karolinska Institutet
HIV Infections
A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience
To assess the efficacy of enfuvirtide (Fuzeon) added to HAART compared to treatment with HAART alone in achieving and maintaining viral load suppression.
- Trial name
- INTENSE (NCT00487188)
- Testing
- Enfuvirtide, Highly active antiretroviral treatment (HAART)
- Where
- 39 sites in United States, Canada and 8 more
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
HIV Infections, Hepatitis C
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in patients naive for HIV and…
- Trial name
- NCT00437476
- Testing
- LPV/r, Nucleoside Reverse Transcriptase Inhibitors, PEG-IFNa 2a
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
HIV Infections
A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen
The purpose of this study is to find out the frequency of the I50L substitution among patients experiencing treatment failure on an atazanavir-containing regimen.
- Trial name
- NCT00135447
- Where
- 84 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Bristol-Myers Squibb
Insomnia, Sleep Efficiency
Feasibility of Non-pharmacological Insomnia Therapy in People Living With HIV
To establish with a prospective randomized placebo-controlled study the feasibility of allied-health personnel-administered cognitive behavioral insomnia therapy (CBTI) as a means of improving HIV/AIDS treatment adherence.
- Trial name
- NCT01804907
- Testing
- Cognitive Behavioral Therapy, Behavioral Modification
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Duke University
HIV Infection
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.
- Trial name
- NCT00234975
- Testing
- Lopinavir/Ritonavir
- Where
- 11 sites in Puerto Rico
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infection
Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
This study will examine whether interleukin-2 (IL-2) plus antiretroviral therapy (ART) slows HIV disease progression in patients with low CD4+ T cell counts compared with patients taking ART alone.
- Trial name
- SILCAAT (NCT00013611)
- Testing
- Proleukin
- Where
- United States
- Volunteers
- 1,695 people
- Sponsor
- University of Minnesota
HIV Infections
TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
This study looked at lipid changes in human immunodeficiency virus type 1 (HIV-1) infected patients when the nucleoside reverse transcriptase inhibitors (NRTIs) in their existing highly active antiretroviral therapy (HAART)…
- Trial name
- TOTEM (NCT00323492)
- Testing
- Truvada, Current HAART regimen
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C, HIV Infections
Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication
The main purpose of this study is to compare the safety, effectiveness and tolerability of using Pegasys with Copegus in people who have both the hepatitis C virus (HCV) genotype 1 and HIV who continue taking HAART (highly active…
- Trial name
- NCT00296972
- Testing
- peg interferon plus ribavirin
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
HIV Infection
Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).
The objectives of this Phase I/II trial is to evaluate the safety, tolerability and immunogenicity of THV01 compared to placebo in HIV-1 infected patients on HAART (highly active antiretroviral therapies).
- Trial name
- NCT02054286
- Testing
- THV01-1, THV01-2
- Where
- 11 sites in Belgium, France
- Volunteers
- 38 people
- Sponsor
- Theravectys S.A.
HIV-1
Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions
In this study, the investigators evaluated a therapeutic HIV-1 DNA vaccine administered with a novel topical application method to 12 chronically HIV-infected cART treated patients.
- Trial name
- Vac09 (NCT01140139)
- Testing
- HIV DNA Vaccine
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Swedish Institute for Infectious Disease Control
HIV Infection
Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)
Access to care and treatment using antiretroviral drugs will be expanded in Vietnam in the next few years. The ANRS 1210 study is a pilot program to evaluate the feasibility of a simplified antiretroviral treatment using three…
- Trial name
- NCT00158470
- Testing
- efavirenz, didanosine, lamivudine
- Where
- 2 sites in Vietnam
- Volunteers
- 100 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Increasing HAART-Induced Immune Restoration With Cyclosporine
The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood.
- Trial name
- NCT00031070
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated)
- Where
- 15 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Maraviroc Immune Recovery Study
Rationale: Improving cellular immunity by means of increasing CD4 cells is one of the goals of antiretroviral therapy in HIV, which is achieved by means of virological suppression.
- Trial name
- MIRS (NCT00875368)
- Testing
- maraviroc
- Where
- 10 sites in Netherlands
- Volunteers
- 85 people
- Sponsor
- S.F.L. van Lelyveld
HIV Infections
Pharmacokinetics of Low Dose Ritonavir
Compare the Pharmacokinetics of ritonavir and saquinavir(using either Saquinavir /Ritonavir 1500/100 mg or 1500/50 mg) Evaluate short term tolerability, safety and toxicity Evaluate if there is any relation between RTV…
- Trial name
- NCT00622206
- Testing
- ritonavir and saquinavir
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
HIV Infection
Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)
Objectives of the study: 1. To verify the safety and the efficacy of the study treatment, defined as the persistent control of the virus' replication at 48 weeks after the simplification to maraviroc + darunavir with ritonavir in…
- Trial name
- GUSTA (NCT01367210)
- Testing
- Maraviroc, Darunavir/r, current antiretroviral therapy with 3 drugs
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Catholic University of the Sacred Heart